Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NYSEAMERICAN:MAIA NASDAQ:PRLD NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.35+0.7%$14.56$12.30▼$20.90$319.57M0.8273,158 shs97,586 shsMAIAMAIA Biotechnology$1.36+4.6%$1.31$0.87▼$3.19$79.04M0.23960,462 shs1.12 million shsPRLDPrelude Therapeutics$4.46-0.7%$4.33$0.75▼$5.54$357.61M1285,469 shs327,388 shsSIGASiga Technologies$4.34+0.5%$4.54$4.09▼$9.62$309.85M0.91430,757 shs291,453 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+0.72%+8.10%+5.43%-1.10%+15.85%MAIAMAIA Biotechnology+4.62%+7.09%+7.94%-9.33%-20.93%PRLDPrelude Therapeutics-0.67%+16.15%-0.45%+30.03%+364.53%SIGASiga Technologies+0.46%+0.23%+4.08%-13.55%-31.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.35+0.7%$14.56$12.30▼$20.90$319.57M0.8273,158 shs97,586 shsMAIAMAIA Biotechnology$1.36+4.6%$1.31$0.87▼$3.19$79.04M0.23960,462 shs1.12 million shsPRLDPrelude Therapeutics$4.46-0.7%$4.33$0.75▼$5.54$357.61M1285,469 shs327,388 shsSIGASiga Technologies$4.34+0.5%$4.54$4.09▼$9.62$309.85M0.91430,757 shs291,453 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+0.72%+8.10%+5.43%-1.10%+15.85%MAIAMAIA Biotechnology+4.62%+7.09%+7.94%-9.33%-20.93%PRLDPrelude Therapeutics-0.67%+16.15%-0.45%+30.03%+364.53%SIGASiga Technologies+0.46%+0.23%+4.08%-13.55%-31.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.33Sell$12.00-21.82% DownsideMAIAMAIA Biotechnology 0.00N/AN/AN/APRLDPrelude Therapeutics 2.40Hold$7.6771.90% UpsideSIGASiga Technologies 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MAIA, SIGA, PRLD, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/18/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/11/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/4/2026PRLDPrelude Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/1/2026PRLDPrelude Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/28/2026PRLDPrelude Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/27/2026PRLDPrelude Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.004/20/2026AMRNAmarin Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/2/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$213.65M1.51$0.36 per share42.22$22.07 per share0.70MAIAMAIA BiotechnologyN/AN/AN/AN/A$0.06 per shareN/APRLDPrelude Therapeutics$12.14M29.26N/AN/A$1.09 per share4.09SIGASiga Technologies$94.57M3.29$0.33 per share12.98$2.78 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)MAIAMAIA Biotechnology-$22.40M-$1.38N/AN/AN/AN/A-284.80%-142.94%8/10/2026 (Estimated)PRLDPrelude Therapeutics-$99.50M-$1.00N/AN/AN/AN/A-118.24%-66.12%8/13/2026 (Estimated)SIGASiga Technologies$23.28M$0.2716.07N/AN/A21.58%10.60%8.94%8/4/2026 (Estimated)Latest MAIA, SIGA, PRLD, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PRLDPrelude Therapeutics-$0.27-$0.13+$0.14-$0.13$4.58 million$4.58 million5/11/2026Q1 2026MAIAMAIA Biotechnology-$0.18-$0.14+$0.04-$0.14N/AN/A5/7/2026Q1 2026SIGASiga TechnologiesN/A-$0.05N/A-$0.05N/A$6.24 million3/23/2026Q4 2025MAIAMAIA Biotechnology-$0.13-$0.08+$0.05-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ALatest MAIA, SIGA, PRLD, and AMRN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/26/2026SIGASiga Technologiesspecial$0.604/7/20264/7/20264/23/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.482.46MAIAMAIA BiotechnologyN/A5.595.59PRLDPrelude TherapeuticsN/A2.032.03SIGASiga TechnologiesN/A3.252.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%MAIAMAIA Biotechnology5.65%PRLDPrelude Therapeutics79.72%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipAMRNAmarin4.21%MAIAMAIA Biotechnology19.81%PRLDPrelude Therapeutics49.20%SIGASiga Technologies2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.97 million20.09 millionOptionableMAIAMAIA Biotechnology960.80 million48.76 millionNot OptionablePRLDPrelude Therapeutics12079.64 million40.46 millionOptionableSIGASiga Technologies4071.72 million69.77 millionOptionableMAIA, SIGA, PRLD, and AMRN HeadlinesRecent News About These CompaniesDiscovering SIGA Technologies And 2 Other Compelling Penny StocksMay 22, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's ChangedMay 15, 2026 | finance.yahoo.comSome Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft EarningsMay 14, 2026 | finance.yahoo.comSIGA (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | fool.comSIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 monthsMay 8, 2026 | msn.comSIGA Technologies, Inc. Q1 2026 Earnings Call SummaryMay 8, 2026 | finance.yahoo.comSIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comSIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business UpdateMay 7, 2026 | globenewswire.comSIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%March 28, 2026 | aaii.comASIGA mpox therapy no longer recommended in EUMarch 27, 2026 | msn.comSiga Technologies Declares Special Dividend of 60 CentsMarch 26, 2026 | marketwatch.comSIGA Declares Special Cash Dividend of $0.60 Per ShareMarch 26, 2026 | globenewswire.comSiga Technologies (NASDAQ:SIGA) Options Surge Hits Nasdaq 100 IndexMarch 19, 2026 | kalkinemedia.comKMpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.March 17, 2026 | barrons.comA Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract ProgressMarch 15, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.3% After Mixed 2025 Results and New Biodefense Contract WinsMarch 15, 2026 | finance.yahoo.comSIGA Technologies Eyes TPOXX Growth As New Contracts Meet Lumpy RevenueMarch 14, 2026 | finance.yahoo.comSIGA Technologies Inc (SIGA) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ...March 11, 2026 | finance.yahoo.comSIGA outlines continued TPOXX global expansion and expects EMA smallpox decision in March 2026March 10, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMAIA, SIGA, PRLD, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$15.35 +0.11 (+0.72%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$15.00 -0.35 (-2.28%) As of 06/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.MAIA Biotechnology NYSEAMERICAN:MAIA$1.36 +0.06 (+4.62%) Closing price 06/15/2026 04:10 PM EasternExtended Trading$1.36 -0.01 (-0.37%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Prelude Therapeutics NASDAQ:PRLD$4.46 -0.03 (-0.67%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$4.28 -0.18 (-4.06%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Siga Technologies NASDAQ:SIGA$4.34 +0.02 (+0.46%) Closing price 06/15/2026 04:00 PM EasternExtended Trading$4.31 -0.03 (-0.69%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
